North America

Vapotherm and Flight Medical Partners to Bring the VentO2ux Ventilator to US Hospitals

New ventilator solution combines critical care performance with portable, easy-to-use design ideal for the Emergency Department...

CG Oncology Reports Promising New Data for Cretostimogene in NMIBC at SUO 2025

Robust clinical pipeline that spans multiple late-stage studies across intermediate- and high-risk NMIBC...

Atraverse Medical Secures FDA Clearance for HOTWIRE RF Generator

Atraverse Medical also approaches first 2,000 successful clinical procedures using the company's innovative HOTWIRE radiofrequency (RF) guidewire...

New Biosensors Advance Personalized Cancer Care

Nanocrine's findings will be published at the American Society for Cell Biology annual conference ...

mlHealth 360 Receives FDA Clearance for Scaida BrainCT-ICH

This clearance establishes Scaida BrainCT-ICH as the first Canadian-developed AI solution for intracranial haemorrhage (ICH) triage to be cleared for clinical use in the United States...

Axogen Announces FDA Approval of Biologics License Application for AVANCE

Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities...

Ob Hospitalist Group Launches Commure’s Autonomous Coding to Support Clinicians and Strengthen Coding Accuracy

Autonomous coding reduces administrative burden and gives clinicians more time to focus on patient care...

BD Launches New Cell Analyser Configurations to Bring Cutting-Edge Capabilities to Labs

Three- and Four-Laser BD FACSDiscover A8 Cell Analysers Expand Accessibility of Spectral, Real-Time Imaging Cell Analysis...

Shoulder Innovations Partners with INS to Introduce a Robotic Platform for Shoulder Arthroplasty

Partnership will expand Shoulder Innovations' Disruptive Ecosystem with Advanced Enabling Technology, Complementing Surgeon and Patient Needs in the ASC...

Alpha Tau Receives FDA Approval to Initiate Trial for Patients with Locally Recurrent Prostate Cancer

FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer...